IVF Couples in UK Bypass Regulations by Sending Embryos Abroad for Genetic Analysis
A growing number of couples undergoing IVF treatment in the UK are exploiting a loophole in British law to obtain genetic analysis of their embryos, which can predict traits such as IQ and height. The data is then sent abroad to companies offering polygenic screening services.
The technique, known as "embryo selection" based on genetic predictions, is not permitted at UK fertility clinics, according to the Human Fertilisation and Embryology Authority (HFEA). However, under data protection laws, patients can request access to their embryos' raw genetic data and have it analyzed abroad in an effort to select healthier or more intelligent offspring.
One US company, Herasight, is capitalizing on this loophole. For $50,000 (Β£37,000), the firm offers a polygenic screening service that analyzes an unlimited number of embryos and provides predictions for traits such as IQ, height, and risk scores for certain health conditions.
The company has already worked with several couples undergoing IVF at UK clinics and has built its algorithms using large genetic databases, including the UK Biobank. However, critics say the technique is unproven and raises broader ethical concerns about a potential stratified society where wealthier people can select the embryos they prefer.
According to one UK fertility clinic founder, Dr Cristina Hickman, rapid advances in embryo screening techniques have left clinics facing "legal and ethical confusion." Hickman believes that polygenic testing should be allowed in the UK, but with strict regulations to ensure it is done ethically.
The HFEA has stated that licensed clinics in the UK are not permitted to perform polygenic screening for embryo selection. However, the authority's position on this issue has been questioned by some critics, who argue that the HFEA's regulation may be unenforceable.
A growing number of couples undergoing IVF treatment in the UK are exploiting a loophole in British law to obtain genetic analysis of their embryos, which can predict traits such as IQ and height. The data is then sent abroad to companies offering polygenic screening services.
The technique, known as "embryo selection" based on genetic predictions, is not permitted at UK fertility clinics, according to the Human Fertilisation and Embryology Authority (HFEA). However, under data protection laws, patients can request access to their embryos' raw genetic data and have it analyzed abroad in an effort to select healthier or more intelligent offspring.
One US company, Herasight, is capitalizing on this loophole. For $50,000 (Β£37,000), the firm offers a polygenic screening service that analyzes an unlimited number of embryos and provides predictions for traits such as IQ, height, and risk scores for certain health conditions.
The company has already worked with several couples undergoing IVF at UK clinics and has built its algorithms using large genetic databases, including the UK Biobank. However, critics say the technique is unproven and raises broader ethical concerns about a potential stratified society where wealthier people can select the embryos they prefer.
According to one UK fertility clinic founder, Dr Cristina Hickman, rapid advances in embryo screening techniques have left clinics facing "legal and ethical confusion." Hickman believes that polygenic testing should be allowed in the UK, but with strict regulations to ensure it is done ethically.
The HFEA has stated that licensed clinics in the UK are not permitted to perform polygenic screening for embryo selection. However, the authority's position on this issue has been questioned by some critics, who argue that the HFEA's regulation may be unenforceable.